DABUR INDIA LTD.
P&L
Quarterly Consolidated
vs Q2 FY25
Dabur India's Q3 Consolidated Revenue Up 3.1% at Rs 3,355 Crore, Operating Profit Up 2.1% at Rs 682 Crore
30 Jan 2025 · 30 Jan 2025, 08:53 pm
Summary
Dabur India Ltd, a leading Science-based Ayurveda major, announced a 3.1% increase in Consolidated Revenue for the third quarter ended December 31, 2024, with Operating Profit up 2.1% YoY. The company reported a 5.6% growth in Constant Currency terms. Dabur's strategic vision has been revised to a three-year cycle due to volatile geopolitical and macroeconomic indicators. The company has expanded its rural distribution network and reported market share gains in key categories.
Key Highlights
- 1
Dabur India's Q3 Consolidated Revenue up 3.1% to Rs 3,355 Crore
- 2
Q3 Operating Profit increased by 2.1% to Rs 682 Crore
- 3
Strategic vision revised to a three-year cycle for agility and alignment with evolving dynamics
- 4
Rural distribution network expanded by 15,000 villages, reaching 131,000 villages
- 5
Market share gains across 95% of the portfolio, led by Hair Oils, Air Fresheners, and Juices & Nectars
- 6
International Business reported strong constant currency growth of 19% in Q3
- 7
Dabur progressing well in meeting long-term sustainability commitments, with a significant improvement in Corporate Sustainability Assessment (CSA) Score for 2024
Management Comments
Mohit Malhotra
Dabur India Limited Chief Executive Officer
We focused on strengthening our competitive edge in the marketplace to gain market share in 95% of our portfolio and enhancing brand superiority to strengthen and consolidate our position in the categories where we operate. With the geopolitical landscape remaining volatile in the short term, shrouded by uncertain macroeconomic indicators, Dabur has decided to revise its strategic Vision cycle from four years to three years to create a more agile organisation that can quickly navigate the challenges and capture the emerging opportunities.
Informational and educational content only. Not investment advice.